Difficult to build a case for this as it is purely speculation and rumor that has highlighted the stock of NASDAQ:CLVS . There has been some option activity which is encouraging and positive trial data which failed to rally the stock. The contrarian long option is going against strong negatives such as, high debt, decreasing pricing power, insider selling and...
*********STRONG WATCH FOR A BREAKOUT ON THIS NAME IN THE COMING WEEKS****** ANALYSTS ARE VERY OPTIMISTIC ON THE PROSPECTS WITH CREDIT SUISSE ISSUING A BUY RATING AND A $29 TARGET WHILE ON MAY THE 8th H.C WAINWRIGHT MAINTAINED A BUY RATING AND A $36 PRICE TARGET.
EARNINGS HIGHLIGHTS
Edited Transcript of Clovis Oncology Inc earnings conference call or...
Bullish view on Clovis Oncology as it breaks $30 price resistance.
CLVS jumped 13% last Wednesday as sales of its Rubraca drug used to treat ovarian cancer patients went up 33% compared to previous quarter.
A few thoughts on CLVS. May not pan out, but this is a bullish scenario.
Reasons the bull scenario could play out from a technical standpoint:
1. Move up to $99 was a clear 5 waves. It looks to have recently completed the ABC correction into a perfect golden pocket 61.8 to 65% retracement.
2. Wave C was an ending diagonal. CLVS has broken out of the diagonal...
Playing Trading Simulator Game:
Short term movement is in positive direction.
5SMA - 20SMA looked good.
Bought 1000 shares at $66.77 on 2JAN18.
I wanted to keep my gains so I ordered a trailing stop of 25 cents on 3JAN18.
The order executed at $67.61 giving me a profit of $840 minus fees.
It was probably a risky entry point.
Next time I'll wait until price is...
CLVS has stochastic divergence at trend line support of an ascending channel. Looking to bounce back up in the channel.
Buy: 74.11
Target: 76.43 - 80.40 (3.13% - 8.49%)
CLVS stock today Oct 16, 2017, at 84.58 and it has tried to break up about four times with four wicks. It appears that there is a good possibility of shorting CLVS in the wedge formation with a target of 77.09.
If CLVS breaks down the wedge, there is a good chance to hit 58-60 level and complete wave 5 down.
The stop loss is set up at 86.41. Good...
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CLVS
